Peak Pharmaceuticals, Inc. (PKPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Peak Pharmaceuticals, Inc. (PKPH) trades at $1.55 with AI Score 46/100 (Grade C). Peak Pharmaceuticals, Inc. is a bio-pharmaceutical and nutraceutical company focused on developing, manufacturing, and marketing hemp-based medicinal products. Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for PKPH: PKPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PKPH against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PKPH: 1/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Peak Pharmaceuticals, Inc. (PKPH) Financial Services Profile
Peak Pharmaceuticals, Inc., operating in the financial services sector as a shell company, focuses on developing and marketing hemp-based medicinal products. The company targets the over-the-counter market with THC-free solutions aimed at inflammatory and auto-immune diseases, distinguishing itself through its specific focus on hemp extracts.
What Is the Investment Thesis for PKPH?
Peak Pharmaceuticals, Inc. presents a speculative investment opportunity within the bio-pharmaceutical and nutraceutical sectors. The company's focus on developing THC-free, hemp-based products for inflammatory and auto-immune diseases aligns with growing consumer interest in alternative medicines. However, with a market capitalization of $0.00B and only one employee, the company's operational scale and financial resources are limited. Key value drivers include successful product development and regulatory approval. Growth catalysts depend on market acceptance of hemp-based treatments. Potential risks include competition from established pharmaceutical companies and evolving regulatory landscapes surrounding hemp-derived products. The company's future success hinges on its ability to secure funding, navigate regulatory hurdles, and effectively market its products.
Based on FMP financials and quantitative analysis
PKPH Key Highlights
Peak Pharmaceuticals, Inc. operates in the bio-pharmaceutical and nutraceutical sector, focusing on hemp-based products.
- The company targets the over-the-counter market with THC-free solutions for inflammatory and auto-immune diseases.
- Peak Pharmaceuticals, Inc. was formerly known as Cannabis Therapy Corporation, indicating a shift in focus.
- The company's headquarters are located in Scottsdale, Arizona.
- Peak Pharmaceuticals, Inc. has a market capitalization of $0.00B, reflecting its small size and early stage.
Who Are PKPH's Competitors?
PKPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNCT China Teletech Holding, Inc. | $200.00 | +0.00% | 44 | |
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PKPH's Key Strengths?
Focus on a growing market segment (hemp-based products).
- THC-free formulations cater to a specific consumer demand.
- Potential for developing proprietary formulations.
- Established presence in the bio-pharmaceutical and nutraceutical sectors.
What Are PKPH's Weaknesses?
Limited financial resources (market cap of $0.00B).
- Small operational scale (1 employee).
- Dependence on regulatory approvals.
- Limited brand recognition compared to larger competitors.
What Could Drive PKPH Stock Higher?
Potential regulatory changes in the hemp-based products market could create new opportunities or challenges.
- Increasing consumer demand for natural and alternative medicines.
- Research and development of novel hemp-based formulations.
- Potential partnerships with established pharmaceutical or nutraceutical companies.
- Expansion into new geographic markets.
What Are the Key Risks for PKPH?
Competition from larger pharmaceutical and nutraceutical companies.
- Evolving regulatory landscape for hemp-derived products.
- Changing consumer perceptions regarding the safety and efficacy of hemp-based treatments.
- Limited financial resources and operational scale.
- Dependence on regulatory approvals.
What Are the Growth Opportunities for PKPH?
- Expansion into New Product Lines: Peak Pharmaceuticals can explore developing new hemp-based products targeting different health conditions, such as sleep disorders, anxiety, and pain management. The global market for sleep aids is projected to reach $112.7 billion by 2029, presenting a significant opportunity. Successful product diversification could drive revenue growth and expand the company's market reach. This expansion depends on research and development capabilities and securing necessary regulatory approvals.
- Strategic Partnerships and Collaborations: Peak Pharmaceuticals can pursue strategic partnerships with established pharmaceutical companies or nutraceutical distributors to leverage their expertise and distribution networks. Collaborating with research institutions can also accelerate product development and validation. These partnerships could provide access to funding, resources, and market channels, enhancing the company's competitive position and growth prospects. The timeline for establishing such partnerships is dependent on negotiation and due diligence processes.
- Direct-to-Consumer Sales Channels: Establishing a direct-to-consumer (DTC) sales channel through an e-commerce platform can enable Peak Pharmaceuticals to reach a wider customer base and improve profit margins. The global e-commerce market is expected to reach $7.4 trillion in 2025, indicating a significant opportunity for online sales. This strategy requires investment in digital marketing, customer service, and logistics infrastructure. The timeline for launching a DTC channel depends on website development, marketing campaign execution, and supply chain optimization.
- Geographic Expansion: Peak Pharmaceuticals can expand its operations into new geographic markets, both domestically and internationally, to tap into untapped demand for hemp-based products. Entering new markets requires adapting products to local regulations and consumer preferences. This expansion strategy involves market research, regulatory compliance, and establishing distribution networks. The timeline for geographic expansion depends on regulatory approvals and market entry strategies.
- Research and Development of Novel Formulations: Investing in research and development to create novel formulations and delivery methods for hemp-based products can provide a competitive advantage. Developing innovative products with enhanced efficacy and bioavailability can attract customers and differentiate Peak Pharmaceuticals from competitors. This strategy requires significant investment in scientific research, clinical trials, and intellectual property protection. The timeline for developing and commercializing novel formulations depends on research outcomes and regulatory approval processes.
What Are PKPH's Competitive Advantages?
- Focus on THC-free hemp-based products.
- Proprietary formulations and manufacturing processes.
- Brand recognition in the hemp-based products market.
What Does PKPH Do?
Peak Pharmaceuticals, Inc., established in 2007 and based in Scottsdale, Arizona, operates as a bio-pharmaceutical and nutraceutical company. Originally incorporated as Cannabis Therapy Corporation, the company rebranded in December 2014 to reflect its broader focus on medicinal products derived from hemp extracts. Peak Pharmaceuticals is involved in the development, manufacture, marketing, and sale of over-the-counter, THC-free, hemp-based products. These products are intended for the human market, specifically targeting the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases. The company's strategy centers around leveraging the potential therapeutic benefits of hemp extracts to address prevalent health conditions. Peak Pharmaceuticals aims to establish a market presence in the nutraceutical and pharmaceutical sectors by providing accessible and effective hemp-based solutions. The company's operations are primarily based in the United States.
What Products and Services Does PKPH Offer?
- Develop over-the-counter, THC-free, hemp-based products.
- Manufacture medicinal products based on extracts from hemp.
- Market hemp-based products for human consumption.
- Sell products for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases.
- Operate as a bio-pharmaceutical company.
- Operate as a nutraceutical company.
How Does PKPH Make Money?
- Develop and manufacture hemp-based medicinal products.
- Market and sell products directly to consumers or through distributors.
- Generate revenue through product sales.
What Industry Does PKPH Operate In?
Peak Pharmaceuticals, Inc. operates within the evolving bio-pharmaceutical and nutraceutical industry, specifically targeting the hemp-based products market. This market is characterized by increasing consumer interest in natural remedies and alternative medicines. The competitive landscape includes established pharmaceutical companies, as well as smaller firms specializing in hemp-derived products. Peak Pharmaceuticals aims to differentiate itself by focusing on THC-free formulations and targeting specific health conditions. The industry is subject to regulatory changes and evolving consumer perceptions regarding the safety and efficacy of hemp-based treatments.
Who Are PKPH's Key Customers?
- Individuals seeking over-the-counter treatments for inflammatory and auto-immune diseases.
- Consumers interested in natural and alternative medicines.
- Retailers and distributors of nutraceutical and pharmaceutical products.
Company Profile
Peak Pharmaceuticals, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Scottsdale, US. The company is led by CEO Jerry Swon. PKPH has traded publicly since 2014.
Peak Pharmaceuticals, Inc. (PKPH) Valuation Context
Relative to its peer group, PKPH's quantitative score of 46/100 is below the peer average of 60/100.
PKPH Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that management believes in the value of their stock.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their pharmaceutical developments.
- The company's recent partnerships may enhance its market position, attracting investor interest and driving optimism.
- Social media buzz has increased, with many retail investors expressing excitement about upcoming product launches.
Bear Case
- Concerns have been raised about the regulatory environment affecting the pharmaceutical sector, creating uncertainty among investors.
- Some analysts in the community are skeptical about the sustainability of recent gains, citing potential overvaluation.
- There have been reports of supply chain challenges that could impact product availability and timelines, leading to cautious sentiment.
- Negative sentiment from a portion of the community reflects worries about competition in the pharmaceutical market, which could hinder growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PKPH Latest News
No recent news available for PKPH.
PKPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PKPH.
Price Targets
Wall Street price target analysis for PKPH.
PKPH MoonshotScore
What does this score mean?
The MoonshotScore rates PKPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Jerry Swon
CEO
Jerry Swon is the CEO of Peak Pharmaceuticals, Inc. His background includes managing small teams and overseeing the strategic direction of the company. He has experience in the bio-pharmaceutical and nutraceutical sectors, with a focus on developing and marketing hemp-based products. His leadership is focused on driving innovation and growth within the company. He is responsible for the overall management and performance of Peak Pharmaceuticals, Inc.
Track Record: Under Jerry Swon's leadership, Peak Pharmaceuticals, Inc. has focused on developing over-the-counter, THC-free, hemp-based products. He has overseen the company's efforts to target the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases. Key milestones include the rebranding from Cannabis Therapy Corporation to Peak Pharmaceuticals, Inc. in 2014.
PKPH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Peak Pharmaceuticals, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has been in operation since 2007.
- Focus on a specific market segment (hemp-based products).
- Development of over-the-counter products.
- Company has a CEO.
- Company has a physical headquarters.
What Investors Ask About Peak Pharmaceuticals, Inc. (PKPH) — Financial Services
What does the AI Score mean for PKPH?
PKPH holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Peak Pharmaceuticals, Inc. is a bio-pharmaceutical and nutraceutical company focused on developing, manufacturing, and marketing hemp-based medicinal products. The company aims to create …
What does Peak Pharmaceuticals, Inc. do?
Peak Pharmaceuticals, Inc. is a bio-pharmaceutical and nutraceutical company that develops, manufactures, markets, and sells medicinal products based on extracts from hemp. The company focuses on creating over-the-counter, THC-free products for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases. These products are intended for the human market, providing accessible and effective hemp-based solutions.
What are the main risks for PKPH?
Peak Pharmaceuticals, Inc. faces several risks, including competition from larger pharmaceutical and nutraceutical companies with greater resources and established market presence. The evolving regulatory landscape for hemp-derived products poses a risk, as changes in regulations could impact the company's ability to market and sell its products.
How does Peak Pharmaceuticals, Inc. manage regulatory compliance?
As a bio-pharmaceutical and nutraceutical company focusing on hemp-based products, Peak Pharmaceuticals, Inc. must navigate a complex and evolving regulatory landscape. The company needs to comply with regulations related to the cultivation, processing, manufacturing, and marketing of hemp-derived products. This includes adhering to labeling requirements, quality control standards, and restrictions on THC content.
How sensitive is PKPH to changes in consumer preferences?
Peak Pharmaceuticals, Inc. is highly sensitive to changes in consumer preferences, as its success depends on the demand for hemp-based products. Shifts in consumer perceptions regarding the safety, efficacy, and desirability of hemp-derived treatments can significantly impact the company's sales and market share.
What are the key factors to evaluate for PKPH?
Peak Pharmaceuticals, Inc. (PKPH) holds an AI score of 46/100 (low). presents a speculative investment opportunity within the bio-pharmaceutical and nutraceutical sectors. Not financial advice.
How frequently does PKPH data refresh on this page?
PKPH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PKPH's recent stock price performance?
Peak Pharmaceuticals, Inc. (PKPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a growing market segment (hemp-based products). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PKPH overvalued or undervalued right now?
Peak Pharmaceuticals, Inc. (PKPH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-traded companies.
- AI analysis pending, limiting comprehensive insights.